Novavax (NVAX) Asset Writedowns and Impairment (2010 - 2026)

Novavax's Asset Writedowns and Impairment history runs 8 years deep, the most recent figure standing at $266000.0 for Q1 2026.

• On a quarterly basis, Asset Writedowns and Impairment changed N/A year-over-year to $266000.0 in Q1 2026; TTM through Mar 2026 was $99.1 million, a 1924.75% increase from a year earlier, with the FY2025 full-year figure at $4.9 million, changed N/A from the prior year.
• Asset Writedowns and Impairment fell to $266000.0 in Q1 2026 per NVAX's latest filing, from $1.5 million in the prior quarter.
• Across five years, Asset Writedowns and Impairment topped out at $155.7 million in Q2 2022 and bottomed at -$5.4 million in Q4 2024.
• The 5-year median for Asset Writedowns and Impairment is $1.6 million (2024), against an average of $32.6 million.
• Across the five-year window, Asset Writedowns and Impairment slumped 93.53% in 2023 and soared 127.58% in 2025, its largest moves.
• Year by year, Asset Writedowns and Impairment stood at $155.7 million in 2022, then slumped by 93.53% to $10.1 million in 2023, then plunged by 153.87% to -$5.4 million in 2024, then surged by 127.58% to $1.5 million in 2025, then tumbled by 82.24% to $266000.0 in 2026.
• Per Business Quant, the three latest NVAX Asset Writedowns and Impairment figures stand at $266000.0 (Q1 2026), $1.5 million (Q4 2025), and $97.0 million (Q3 2025).